FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The purpose of the present study was to evaluate the activity and the tolerability of the FOLFIRI regimen, administered as second-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer after the failure of a gemcitabine-based regimen.
Patients with locally advanced/metastatic disease who received a first-line chemotherapy (one line only) with gemcitabine ± platinoid (cisplatin, oxaliplatin) and who had measurable disease conform with the RECIST criteria were eligible for the study.
FOLFIRI consists of irinotecan 180 mg/m2 iv on day 1, leucovorin (l-form) 200 mg/m2 iv on day 1 and 2, 5-FU 400 mg/m2 iv bolus on days 1 and 2, and 5-FU 600 mg/m2 iv by ci for 22 h on days 1 and 2, repeated every 2 weeks. The primary end point was the response rate.
Among the 50 enrolled patients, 4 partial responses (PR) (8 %) and 14 stable diseases were observed, for a disease control rate of 18/50 (36 %). Forty-one patients (82 %) have been pretreated with cisplatin/oxaliplatin+gemcitabine as first-line chemotherapy. The median progression-free and overall survivals were 3.2 and 5 months, respectively. The 6-month survival rate was 32 %. Grade 3–4 neutropenia and diarrhea occurred in 10 (20 %) and 6 (12 %) patients, respectively.
The FOLFIRI regimen showed a modest clinical activity in this quite heavily pretreated patients’ population with locally advanced or metastatic pancreatic cancer with a manageable toxicity profile.
- FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
Cancer Chemotherapy and Pharmacology
Volume 69, Issue 6 , pp 1641-1645
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Pancreatic cancer
- Industry Sectors
- Author Affiliations
- 1. Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
- 2. Medical Oncology Unit, C. Poma Hospital, Mantua, Italy
- 3. Medical Oncology Unit, Treviglio-Caravaggio Hospital, Treviglio, Italy
- 4. Medical Oncology Unit, S. Paolo Hospital, Milan, Italy
- 5. Medical Oncology Unit, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy
- 6. Medical Oncology Unit, Ospedali Riuniti Marche Nord, Presidio San Salvatore, Pesaro, Italy
- 7. Medical Oncology DH, Ospedale di Sondalo, Sondalo, Italy
- 8. Medical Oncology Unit, Ospedale San Carlo, Potenza, Italy
- 9. Medical Oncology Unit, Ospedale Don Luigi di Liegro, Gaeta, Italy
- 10. Department of Surgery, Fondazione Poliambulanza, Brescia, Italy
- 11. Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy